Does rosuvastatin reduce atherosclerosis and related cardiac pathology in SR-B1-/-/apoE-/- double knockout mice?
Rosuvastatin reduces atherosclerosis and cardiac pathology in a mouse model independently of cholesterol lowering, potentially via reduction of oxidized phospholipids and macrophage foam cell formation.
Rosuvastatin protected SR-B1-/-/apoE-/- mice against atherosclerosis and platelet accumulation in coronary arteries and attenuated myocardial fibrosis and cardiomegaly, despite increased plasma total cholesterol. The ability of rosuvastatin to reduce oxidized phospholipids in atherosclerotic plaques and inhibit macrophage foam cell formation may have contributed to this protection.
Yu et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: